ANZCTR search results

This study aims to understand whether different types of knee sounds are associated with knee issues. We also would like to understand perceptions that people have regarding their creaky knees and usefulness of an Exercise Physiology assessment session for their knee function and health. The study will ask people, with/without knee osteoarthritis, to attend a 1-hour knee assessment session at the University of Sydney. In this session knee health will be assessed, knee sounds recorded, and exercise advice provided. Three months later the participants will be interviewed about their knee health and if they found the AEP session useful.

The purpose of this study is to determined whether the addition of a PET scan to conventional CT scans improves the diagnostic accuracy and/or changes the management for patients newly found to have a kidney tumour. Who is it for? You may be eligible if you are an adult who has recently been diagnosed with a kidney tumour. Study details PET scans work by injecting a "tracer" that accumulates in specific tissue types and show as "hot spots" on a scan. We will be comparing two types of tracer that have been shown to have affinity for renal tumours: Prostate-Specific Membrane Antigen (PSMA) and Fludeoxyglucose (FDG). As such all participants in this study will be asked to have both a PSMA PET and an FDG PET within 21 days of enrolment. The scans may be performed on the same day, or require different visits. There is a small risk of bruising or infection at the injection site. Each scan involves a small radiation dose which is within safe limits. Participants will also complete a health-related quality of life questionnaire at enrolment and after completing the scans. It is hoped that this study will determine whether PET scans will improve diagnostic accuracy both by identifying areas of tumour not seen on CT, and by ruling out areas that are suspicious on CT.

Anal high grade squamous intraepithelial lesions (HSIL) are caused by high-risk human papillomavirus (HRHPV) and may develop into anal cancer. Anal cancer is rare in the general community, however people who live with HIV (PLHIV) are at higher risk. Anal HSIL is detected by high resolution anoscopy (HRA). The PANTHER study aims to evaluate the effectiveness, acceptability, and tolerability of electrocautery treatment in PLHIV with persistent intra-anal HSIL.

People with mental illness often have to accept medication and other treatments in the community through the use of community treatment orders (CTOs). Yet forced treatment remains one of the most contentious issues in mental health service delivery; its efficacy is unresolved, its usage is irregular and unequal, and it raises serious ethical and human rights concerns. Responses to these debates must be informed by valid and reliable data. This study will be the first to investigate the justifications for CTOs across Australia to allow greater understanding of the variance in rates of CTOs and enable appropriate action by stakeholders. The primary aim of this study is to analyse data on the sociodemographic and clinical features of people on CTOs across Australia comparing similar services across Australia to understand the wide variation in their use nationwide.

People with mental illness often have to accept medication and other treatments in the community through the use of community treatment orders (CTOs). Yet forced treatment remains one of the most contentious issues in mental health service delivery; its efficacy is unresolved, its usage is irregular and unequal, and it raises serious ethical and human rights concerns. Responses to these debates must be informed by valid and reliable data. This study will be the first to investigate the justifications for CTOs across Australia to allow greater understanding of the variance in rates of CTOs and enable appropriate action by stakeholders. The primary aim of this study is to understand differences in sociodemographic, clinical and health service use patterns (hospital and community) between individuals discharged onto CTOs compared to voluntary treatment.

This study aims to assess whether use of a new near infrared imaging device (PTeye device) during thyroid and some parathyroid operations enables surgeons to confidently identify parathyroid glands. Who is it for? You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with thyroid disease, including primary hyperparathyroidism and thyroid cancer who will be undergoing thyroid or parathyroid surgery for exploration and/or tissue removal purposes. Study details Participants who choose to enrol in this study will be randomly allocated by chance (similar to flipping a coin) to one of two groups. Both groups will undergo their scheduled thyroid/parathyroid surgery per standard procedures, however one of the groups will also have their tissue imaged using the PTeye device. It is anticipated that use of the PTeye device will add 5 minutes to the overall procedure time. It is hoped this research will determine whether use of the PTeye device enables surgeons to more confidently identify parathyroid tissue during surgery. By assisting the surgeon in correctly identifying parathyroid glands, this device may improve the quality of the operation performed on the patient.

The aim of this study is to determine the feasibility, safety, and acceptability of short-term humidified flow therapy (myAirvo 3TM) in people living with respiratory conditions in the SESLHD community. The hypothesis is that myAirvo 3 is feasible, safe and acceptable to be used in the community and will assist sputum burden and/or breathlessness.

This study is investigating whether routine heart monitoring during treatment with HER2-directed therapies for patients with breast cancer can be simplified. Who is it for? You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with HER2-positive breast cancer and will be undergoing treatment for your cancer that is targeted at the HER2-cancer cell receptors. Study details All participants who choose to enrol in this study will be randomly allocated by chance (similar to flipping a coin) to one of four groups. Participants allocated to the first group will be asked to attend the standard heart care monitoring (full scanning protocol) every 3 months for one year. Participants allocated to the second group will be asked to attend a shorter scanning protocol (abbreviated protocol) every 3 months for one year. Participants allocated to the third and fourth groups will be asked to attend either the full scanning protocol or the abbreviated protocol, but only every 6 months for one year. It is hoped this research will determine whether fewer surveillance monitoring visits are still able to detect any changes in heart health for patients with breast cancer. If this study does indicate that fewer monitoring visits are safe, it could reduce the burden associated with cancer care on patients with breast cancer.

This trial is evaluating a new imaging method, XV LVAS, which generates a 4D report of lung structure and function. This will be used to evaluate the increase in lung function reported in children with cystic fibrosis when starting the modulator therapy ETI (elexacaftor/tezacaftor/ivacaftor). Standard lung function tests will be compared to XV LVAS scan before and after commencement of ETI treatment. This will demonstrate the safety and clinical utility of XV LVAS scans in children and further characterise the improvement of lung function on commencement of ETI therapy.

Neonatal stroke occurs in up to 1 in 2,500 live births and can be defined as disturbances in the blood supply to the brain and includes an acute ischemic event. Up to 60% of babies diagnosed with stroke will have atypical neurological development and brain injury, including epilepsy and cerebral palsy. Current standard of care focusses on diagnosis and prompt stabilisation of symptoms such as seizures. There are no specific interventions to protect the developing brain or prevent the progression of injury. However, stem cells, particularly mesenchymal stem cells (MSCs), are a potential treatment for neonatal stroke, where early therapy may minimise lifelong impairment. This Phase I dose escalation trial assesses the safety of early and repeated systemic (intravenous) administration of MSCs for neonatal stroke at both 2- and 5-million cells/kg body weight.